Fortitude Family Office’s Aclaris Therapeutics ACRS Stock Holding History

Fortitude Family Office’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$296	Buy	+56	New	+$250	﹤0.01%	2057

Other funds holding ACRS

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

CRA Financial Services Northfield, New Jersey $868M AUM 25.66% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Fortitude Family Office's ACRS Position: Q2 2026 in Review

Fortitude Family Office opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 56 shares worth $296. The stake represents ﹤0.01% of the portfolio and ranks #2057 among its holdings.

15 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Fortitude Family Office held 56 shares of Aclaris Therapeutics worth $296 as of Q2 2026.
Aclaris Therapeutics was a new Fortitude Family Office position in Q2 2026.
Aclaris Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2057 holding.
15 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.